Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JNJ
JNJ
J&J quietly punts a pair of early-stage bispecifics for solid tumors
Endpoints
Thu, 01/26/23 - 10:45 am
JNJ
bispecific antibodies
solid tumors
Sales of J&J, Legend cell therapy plateau amid production challenges
BioPharma Dive
Wed, 01/25/23 - 10:57 pm
JNJ
Legend Biotech
gene therapy
Carvykti
Multiple Myeloma
3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023
Motley Fool
Wed, 01/25/23 - 10:28 am
JNJ
COVID-19
consumer health
foreign exchange rates
J&J reiterates 2025 sales goal despite looming Stelara exclusivity loss, global economic challenges
Endpoints
Tue, 01/24/23 - 06:36 pm
JNJ
revenue
earnings
Stelara
Morphic Loses Another Big Pharma as J&J Bails on Research Deal
BioSpace
Mon, 01/23/23 - 11:13 am
JNJ
Janssen
Morphic Therapeutic
R&D
A year of two halves for US approvals
EP Vantage
Thu, 01/19/23 - 09:38 am
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
J&J packs up HIV vaccine after failing phase 3 trial
Fierce Biotech
Wed, 01/18/23 - 11:06 am
JNJ
vaccines
HIV
HIV vaccines
clinical trials
Few big bangs in a quiet year for medtech mergers
EP Vantage
Wed, 01/11/23 - 10:46 am
M&A
Medtech
JNJ
Abiomed
Quidelortho
Ortho Clinical Diagnostics
Coloplast
Atos Medical
ICU Medical
Smiths Medical
Boston Scientific
Baylis Medical
JPM23: J&J stayed in the back seat during Horizon bidding war, CEO says
Fierce Pharma
Tue, 01/10/23 - 06:32 pm
JNJ
Horizon Therapeutics
M&A
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Novo Nordisk, AstraZeneca and Lilly will top pharma's revenue growth in 2023: report
Fierce Pharma
Sun, 01/8/23 - 09:57 pm
Pfizer
Merck
JNJ
Novo Nordisk
AstraZeneca
Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to stretch cash
Fierce Biotech
Fri, 01/6/23 - 09:43 am
Fate Therapeutics
JNJ
cell therapy
layoffs
Ready for takeoff: J&J's consumer health unit Kenvue files for official separation
Endpoints
Thu, 01/5/23 - 05:02 pm
JNJ
IPOs
consumer health
Kenvue
spinoffs
The biggest-selling pharma companies of 2023
EP Vantage
Wed, 01/4/23 - 05:20 pm
Pfizer
Merck
JNJ
Novartis
AbbVie
Roche
Biggest Medtech Winners Going into 2023
Medical Devices and Diagnostics Industry
Tue, 01/3/23 - 10:00 am
Medtech
digital health
hearing aids
JNJ
Abiomed
M&A
device manufacturing
semiconductors
women executives
Johnson & Johnson is Investing Billions in Clinical Care Solutions
Forbes
Wed, 12/28/22 - 08:30 pm
JNJ
Abiomed
M&A
J&J leads $85M investment in HistoSonics ahead of liver cancer device authorization
Medtech Dive
Wed, 12/14/22 - 10:41 am
JNJ
funding
venture capital
HistoSonics
liver cancer
Medtech
Edison
devices
JNJ Innovation
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Fri, 12/9/22 - 10:37 am
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
On its annual list of price hike offenders, ICER calls out Bausch's Xifaxan, J&J's Invega
Fierce Pharma
Wed, 12/7/22 - 10:10 am
ICER
drug pricing
Bausch Health
Xifaxan
JNJ
Invega
Pages
« first
‹ previous
…
9
10
11
12
13
14
15
16
17
…
next ›
last »